Home » LC-FAOD »
Introduction
The ACADVL gene, which stands for acyl-CoA dehydrogenase very long chain, is located on chromosome 17p13.1. It has 20 exons spanning ~5.4kb and encodes a 655 amino acid protein (Very Long-Chain Acyl-CoA Dehydrogenase or VLCAD). VLCAD is targeted to the inner mitochondrial membrane where it catalyzes the first step of the mitochondrial fatty acid beta-oxidation pathway (1) breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats (2). This acyl-Coenzyme A dehydrogenase is specific to long-chain and very-long-chain fatty acids (1). Among the different mitochondrial acyl-CoA dehydrogenases, VLCAD acts specifically on acyl-CoAs with saturated 12 to 24 carbons long primary chains (2).
Predominantly expressed in heart and skeletal muscle also detected in kidney and liver, a deficiency in this gene product reduces myocardial fatty acid beta-oxidation and is associated with cardiomyopathy. The enzyme was found to catalyze the major part of mitochondrial palmitoyl-CoA dehydrogenation in liver, heart, skeletal muscle, and skin fibroblasts (3).
More than 450 unique disease-causing variants in the ACADVL gene have been identified in VLCAD patients and are represented in this database (4). The variants occur across the entire length of the gene and include frameshift, splice site, copy-number, nonsense and missense variants.
Variant List
To see more information, click on the Variant in the table. Hover on the Variant in the table to see its location on the gene. For more information on table headers, HGVS nomenclature, and ACMG classification please use the following links here.